U.S. stock night market volatility: Fractyl Health fell 8.38% in after-hours trading, as positive clinical data fails to mask market pessimism and regulatory challenges

U.S. Stock Night Market Movements Fractyl Health fell 8.38% in the night market. Based on recent key news: On January 29, Fractyl Health announced six-month randomized trial data for the Revita treatment, showing that patients maintained good weight and improved cardiometabolic status after discontinuing GLP-1. This data enhanced market confidence in its products but failed to prevent the stock price from falling. On January 29, the company announced that it had applied for FDA feedback on the De Novo pathway for Revita, expecting to receive a response in the second quarter of 2026. This move indicates the company's positive progress in regulatory pathways, but the market reaction remains negative. On January 29, Fractyl Health released detailed documents on the clinical results and regulatory progress of the Revita endoscopic procedure, emphasizing its commercial readiness and safety. Despite the positive data, it failed to boost the stock price. The healthcare industry faces regulatory challenges and high liquidity. Stocks with High Trading Volume in the Industry Intuitive Surgical fell 0.17% in the night market. Based on recent news: On January 29, Intuitive Surgical's Chief Medical Officer Myriam Curet reported selling common stock of the company. This news may raise market concerns about insider confidence, leading to a drop in stock price. On January 29, Intuitive Surgical board member Gary S. Guthart also reported selling common stock of the company. The consecutive insider selling actions further exacerbated market unease, affecting stock performance. On January 27, TipRanks and Google reaffirmed a buy rating for Intuitive Surgical, setting a target price of $594. Despite the positive rating, the market reacted more strongly to the insider selling, leading to a decline in stock price. The medical device industry has been volatile recently, requiring attention to policy changes. ClearPoint Neuro had a trading volume of $10,500. Based on recent key news: On January 27, ClearPoint Neuro's CEO Joseph Burnett reported selling common stock of the company. This move may lead to a decline in market confidence in the company's management, subsequently affecting the stock price. On January 28, analysts maintained a hold rating on ClearPoint Neuro, believing that five other stocks offer better investment value. This may lead to decreased investor interest in the stock. On January 27, ClearPoint Neuro's success in partner projects could significantly enhance its market value, although current developments are positive, they have not yet had a direct impact on the stock price. Market confidence in management is declining, and trading is active. HeartBeam fell 1.99% in the night market. There has been no significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation no_news